Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis

13:34 EST 6 Dec 2019 | Xconomy

Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients. The Acadia (NASDAQ: ACAD) drug pimavanserin (Nuplazid) is currently approved for treating psychosis associated with Parkinson’s disease. But the San Diego-based company has also been testing the drug in dementia-related psychosis (DRP), which […]

Original Article: Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis


More From BioPortfolio on "Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...